Influence of depressive symptoms on dopaminergic treatment of Parkinson’s disease
Alexandru eHanganu, Clotilde eDegroot, Oury eMonchi and 7 more
Frontiers in Neurology · 2014
doi:10.3389/fneur.2014.00188 (opens in a new tab)
We email you when a new notice or a question about this paper appears.
Abstract
Introduction: Depressive symptoms are very common in patients with Parkinson’s disease and have a significant impact on the quality of life. Dopaminergic medication has been shown to have an influence on the development of depressive symptoms.Material and Methods: The present study analyzed two groups of non-demented patients with Parkinson’s disease, with and without depressive symptoms, and reported the correlations between antiparkinsonian medication (specifically levodopa and dopaminergic agonists) with depressive symptoms.Results: A strong statistically significant positive correlation between levodopa dosages and the level of depressive symptoms has been revealed, suggesting that higher levodopa dosages correlate with a worsening of depressive status. No significant correlation was found with dopamine agonists.Discussion: The results of this study show that in patients with Parkinson’s disease, higher levodopa dosages correlate with worse depressive symptoms. From this point of view, Parkinson’s disease patients need to be better diagnosed with respect to depressive symptoms and need additional treatment adjustment when clinical manifestations of depression are present. Clinicians must be aware that dopaminergic drugs are not sufficient to alleviate depressive symptoms.
Abstract licence: CC BY
Reads
Read by people on this page
None yet.
Checked or read by AI through naulon
None yet.
A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.
Are you an author?
Is this your paper?
Claim it to add your note and be paid when agents cite it. Free.